The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Integrins as therapeutic targets: lessons and opportunities
Open accessAbstract
The integrins are a large family of cell adhesion molecules that are essential for the regulation of cell growth and function. The identification of key roles for integrins in a diverse range of diseases, including cancer, infection, thrombosis and autoimmune disorders, has revealed their substantial potential as therapeutic targets. However, so far, pharmacological inhibitors for only three integrins have received marketing approval. This article discusses the structure and function of integrins, their roles in disease and the chequered history of the approved integrin antagonists. Recent advances in the understanding of integrin function, ligand interaction and signalling pathways suggest novel strategies for inhibiting integrin function that could help harness their full potential as therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
New Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404073301402 · Cited by 2,589
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin
Yednock, T. A., Cannon, C., Fritz, L. C., Sanchez-Madrid, F., Steinman, L., & Karin, N. (1992) · Nature · doi:10.1038/356063a0 · Cited by 1,737
Xiong, J.-P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S. L., & Arnaout, M. A. (2002) · Science · doi:10.1126/science.1069040 · Cited by 1,613
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Cited by
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757
Mas-Moruno, C., Rechenmacher, F., & Kessler, H. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794728639 · Cited by 647
Kapp, T. G., Rechenmacher, F., Neubauer, S., Maltsev, O. V., Cavalcanti-Adam, E. A., Zarka, R., Reuning, U., Notni, J., Wester, H.-J., Mas-Moruno, C., et al. (2017) · Scientific Reports · doi:10.1038/srep39805 · Cited by 620
The immunological and metabolic landscape in primary and metastatic liver cancer
Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L., & Heikenwalder, M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00383-9 · Cited by 616
Fibrosis-dependent mechanisms of hepatocarcinogenesis
Zhang, D. Y., & Friedman, S. L. (2012) · Hepatology · doi:10.1002/hep.25670 · Cited by 444
“When organized into focal adhesions on the cell surface, integrins promote growth and survival by activating the phosphoinositide 3 kinase (PI3K) and mitogen-activated protein kinase (MAPK) signaling cascades.(17) Increased ECM may stimulate integrin signaling in hepatocytes, thereby enhancing the growth and survival…”
Integrins as therapeutic targets
Goodman, S. L., & Picard, M. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.04.002 · Cited by 376
Baglieri, J., Brenner, D. A., & Kisseleva, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071723 · Cited by 341
Biagioli, M., Carino, A., Cipriani, S., Francisci, D., Marchianò, S., Scarpelli, P., Sorcini, D., Zampella, A., & Fiorucci, S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700183 · Cited by 327
Singh, R. K., Kumar, S., Prasad, D. N., & Bhardwaj, T. R. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.001 · Cited by 282
Rizvi, I., Gurkan, U. A., Tasoglu, S., Alagic, N., Celli, J. P., Mensah, L. B., Mai, Z., Demirci, U., & Hasan, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216989110 · Cited by 234
Integrins as receptor targets for neurological disorders
Wu, X., & Reddy, D. S. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.008 · Cited by 175
“However, the disadvantages associated with antibody therapeutics are the high cost of production, the need for intravenous administration, and the propensity for host immunogenicity and infusion reactions (Cox et al., 2010; Millard et al., 2011).”
InfluentialProtease-Resistant Peptides for Targeting and Intracellular Delivery of Therapeutics
Lucana, M. C., Arruga, Y., Petrachi, E., Roig, A., Lucchi, R., & Oller-Salvia, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122065 · Cited by 102
Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins: Miniperspective
Miller, L. M., Pritchard, J. M., Macdonald, S. J. F., Jamieson, C., & Watson, A. J. B. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01711 · Cited by 48
Crippa, M., Bersini, S., Gilardi, M., Arrigoni, C., Gamba, S., Falanga, A., Candrian, C., Dubini, G., Vanoni, M., & Moretti, M. (2021) · Lab on a Chip · doi:10.1039/d0lc01011a · Cited by 37
A new peptide ligand for colon cancer targeted delivery of micelles
Ren, Y., Mu, Y., Song, Y., Xie, J., Yu, H., Gao, S., Li, S., Peng, H., Zhou, Y., & Lu, W. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1077293 · Cited by 34
Protein-Protein Interactions as Drug Targets
Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9
Metadata
- Authors
- Cox, D., Brennan, M., & Moran, N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-10
- Volume
- 9
- Issue
- 10
- Pages
- 804-820
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1966022051
- Cited by
- 456
- References
- 167
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.